Evidence map›Paper›PMID 42513171›Full record

ArticleMolecules (Basel, Switzerland)2026

RBM5 Acts as a Tumor Suppressor in Breast Cancer Through Binding to G-quadruplexes in the BAP1 Gene Promoter to Activate Its Expression.

Yingzhou Li, Wenmeng Wang, Guangyue Li, Hai Wang, Suixin Cong, Cuicui Yang, Biao Ma, Dangdang Li, Guangchao Sui

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yingzhou LiCollege of Life Science, Northeast Forestry University, Harbin 150040, China.
Wenmeng WangCollege of Life Science, Northeast Forestry University, Harbin 150040, China.
Guangyue LiInstitute of Biology, Westlake Institute for Advanced Study, Hangzhou 310030, China.ORCID 0009-0003-7189-5796
Hai WangCollege of Life Science, Northeast Forestry University, Harbin 150040, China.
Suixin CongCollege of Life Science, Northeast Forestry University, Harbin 150040, China.
Cuicui YangCollege of Life Science, Northeast Forestry University, Harbin 150040, China.
Biao MaCollege of Life Science, Northeast Forestry University, Harbin 150040, China.
Dangdang LiCollege of Life Science, Northeast Forestry University, Harbin 150040, China.ORCID 0000-0001-6407-9705
Guangchao SuiCollege of Life Science, Northeast Forestry University, Harbin 150040, China.ORCID 0000-0002-8164-5585

Funding

National Natural Science Foundation of China 82472721, 82273107, 81872293, 32470571
6 · The paper itself

Abstract

As a member of the RNA-binding motif protein (RBM) family, RBM5 is a characterized tumor suppressor in lung and prostate cancers, with critical roles in alternative splicing of apoptosis- and cell cycle-related genes. However, its direct capacity to regulate gene transcription remains unreported. Here, we identified that RBM5 was significantly downregulated in breast cancer cells and clinical specimens, especially in the basal-like subtype. RBM5 overexpression attenuated breast cancer cell malignancy, while RBM5 knockdown exerted opposite effects. Among genes with promoter G-quadruplex (G4) motifs, RBM5 was positively correlated with multiple tumor suppressors, including BAP1, but uncorrelated with the oncogene MYC. RBM5 bound to G4 motifs in both MYC and BAP1 promoters, but differentially modulated G4 structure stability: it destabilized MYC-G4 while stabilizing BAP1-G4. Mechanistically, either the RRM1 or the RRM2 domain was sufficient for MYC-G4 binding, whereas both domains were required for BAP1-G4 interaction. RBM5 manipulation regulated endogenous BAP1 but not MYC expression. BAP1 overexpression reversed the protumorigenic effects of RBM5 knockdown in cellulo and tumor growth in a xenograft mouse model. Collectively, we reveal that RBM5 acts as a breast cancer tumor suppressor via directly binding the BAP1 promoter G4 to transcriptionally activate BAP1 expression.

Indexed as

Breast NeoplasmsCell Cycle ProteinsDNA-Binding ProteinsGene Expression Regulation, NeoplasticG-QuadruplexesPromoter Regions, GeneticRNA-Binding ProteinsTumor Suppressor ProteinsUbiquitin ThiolesteraseAnimalsCell Line, TumorFemaleHumansMiceProtein BindingBAP1 protein, humanCell Cycle ProteinsDNA-Binding ProteinsRBM5 protein, humanRNA-Binding ProteinsTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1breast cancerG-quadruplexRBM5tumor suppressor

Identifiers

PMID42513171
PMCPMC13415644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.